Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise that encompasses the entire lifecycle of drug development, from pioneering research and development to manufacturing, importation, marketing, and worldwide distribution of its medicinal products. Its extensive and diverse portfolio features numerous key pharmaceutical offerings: Oncology: This includes trastuzumab deruxtecan (an anti-HER2 antibody-drug conjugate for cancer treatment), gefitinib for malignant tumors, bicalutamide for prostate cancer, and tamoxifen, an anti-breast cancer agent. Cardiovascular and Metabolic Health: The company provides teneligliptin and a combination of teneligliptin/canagliflozin for managing type 2 diabetes mellitus, along with colesevelam for both hypercholesterolemia and type 2 diabetes. Other notable products in this area are prasugrel, an antiplatelet agent; edoxaban, an anticoagulant; olmesartan, an antihypertensive; and pravastatin for hypercholesterolemia. Neurology and Pain Management: Offerings include mirogabalin for pain relief, lacosamide as an anti-epileptic agent, memantine for Alzheimer's disease, and loxoprofen, an anti-inflammatory analgesic. Bone Health: Denosumab is available for conditions like osteoporosis and other bone disorders. Gastrointestinal and Other Specialized Treatments: This category features esomeprazole for ulcer treatment, silodosin for dysuria, and ferric carboxymaltose and iron sucrose injections to address anemia. Infectious Diseases and Immunology: Daiichi Sankyo markets laninamivir for anti-influenza treatment, levofloxacin as an antibacterial agent, and a range of vaccines including adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. Beyond prescription medications, the company also supplies a variety of consumer healthcare products: Over-the-Counter Remedies: Lulu, a combination cold remedy, and Loxonin S, an antipyretic/anti-inflammatory analgesic. Dermatology and Personal Care: Transino, aimed at improving melasma and treating spots/freckles; Minon skincare products; and oral care solutions like Breath Labo and Clean Dental. Furthermore, Daiichi Sankyo's operations extend to pharmaceuticals and drugs for animals, cosmetics, medical equipment, various food products, drinking water, and active pharmaceutical ingredients (APIs) and intermediates. The company is also engaged in strategic collaborations, notably with Guardant Health to develop Guardant360 CDx, a companion diagnostic specifically for Enhertu in patients with advanced metastatic non-small cell lung cancer. Established in 1899, Daiichi Sankyo Company, Limited maintains its corporate headquarters in Tokyo, Japan.